Literature DB >> 15905560

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.

Rajatava Basu1, Suniti Bhaumik, Jayati Mookerjee Basu, Kshudiram Naskar, Tripti De, Syamal Roy.   

Abstract

The emergence of an increasing number of Leishmania donovani strains resistant to pentavalent antimonials (SbV), the first line of treatment for visceral leishmaniasis worldwide, accounts for decreasing efficacy of chemotherapeutic interventions. A kinetoplastid membrane protein-11 (KMP-11)-encoding construct protected extremely susceptible golden hamsters from both pentavalent antimony responsive (AG83) and antimony resistant (GE1F8R) virulent L. donovani challenge. All the KMP-11 DNA vaccinated hamsters continued to survive beyond 8 mo postinfection, with the majority showing sterile protection. Vaccinated hamsters showed reversal of T cell anergy with functional IL-2 generation along with vigorous specific anti-KMP-11 CTL-like response. Cytokines known to influence Th1- and Th2-like immune responses hinted toward a complex immune modulation in the presence of a mixed Th1/Th2 response in conferring protection against visceral leishmaniasis. KMP-11 DNA vaccinated hamsters were protected by a surge in IFN-gamma, TNF-alpha, and IL-12 levels along with extreme down-regulation of IL-10. Surprisingly the prototype candidature of IL-4, known as a disease exacerbating cytokine, was found to have a positive correlation to protection. Contrary to some previous reports, inducible NO synthase was actively synthesized by macrophages of the protected hamsters with concomitant high levels of NO production. This is the first report of a vaccine conferring protection to both antimony responsive and resistant Leishmania strains reflecting several aspects of clinical visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905560     DOI: 10.4049/jimmunol.174.11.7160

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  93 in total

1.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  A time course study on prothrombotic parameters and their modulation by anti-platelet drugs in hyperlipidemic hamsters.

Authors:  Vishal Singh; Manish Jain; Prem Prakash; Ankita Misra; Vivek Khanna; Rajiv Lochan Tiwari; Ravi Shankar Keshari; Shivendra Singh; Madhu Dikshit; Manoj Kumar Barthwal
Journal:  J Physiol Biochem       Date:  2011-02-01       Impact factor: 4.158

3.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

4.  Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.

Authors:  Shraddha Kumari; Mukesh Samant; Prashant Khare; Pragya Misra; Sujoy Dutta; Bala Krishna Kolli; Sharad Sharma; Kwang Poo Chang; Anuradha Dube
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

5.  9-O-acetylated sialoglycoproteins are important immunomodulators in Indian visceral leishmaniasis.

Authors:  Angana Ghoshal; Sumi Mukhopadhyay; Bibhuti Saha; Chitra Mandal
Journal:  Clin Vaccine Immunol       Date:  2009-04-29

6.  Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells.

Authors:  Subha Banerjee; June Ghosh; Subha Sen; Rajan Guha; Ranjan Dhar; Moumita Ghosh; Sanchita Datta; Bikramjit Raychaudhury; Kshudiram Naskar; Arun Kumar Haldar; C S Lal; K Pandey; V N R Das; Pradeep Das; Syamal Roy
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

7.  Molecular identification of an old clinical isolate of Indian Kala-azar.

Authors:  Madhumita Manna; Supriya Khanra
Journal:  J Parasit Dis       Date:  2016-06-04

8.  In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

Authors:  E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

9.  Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.

Authors:  Yasuyuki Goto; Lisa Y Bogatzki; Sylvie Bertholet; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2007-08-20       Impact factor: 3.641

Review 10.  The genetics of Leishmania virulence.

Authors:  Eugenia Bifeld; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.